Cubist Systematic Strategies LLC Purchases Shares of 185,813 Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Cubist Systematic Strategies LLC purchased a new stake in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 185,813 shares of the biopharmaceutical company’s stock, valued at approximately $67,000. Cubist Systematic Strategies LLC owned about 0.09% of Sangamo Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of SGMO. State Board of Administration of Florida Retirement System lifted its position in shares of Sangamo Therapeutics by 61.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 23,650 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Sangamo Therapeutics in the 2nd quarter valued at approximately $89,000. Marshall Wace LLP raised its position in shares of Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 207,476 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Sangamo Therapeutics in the 1st quarter valued at approximately $331,000. Finally, Renaissance Technologies LLC raised its position in shares of Sangamo Therapeutics by 58.8% in the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock valued at $1,479,000 after purchasing an additional 1,528,600 shares during the last quarter. 56.93% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Trading Up 2.2 %

SGMO opened at $0.99 on Thursday. Sangamo Therapeutics, Inc. has a 12-month low of $0.29 and a 12-month high of $1.48. The firm has a market capitalization of $205.85 million, a PE ratio of -0.53 and a beta of 1.23. The firm has a 50 day moving average of $0.86 and a two-hundred day moving average of $0.65.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). Sangamo Therapeutics had a negative return on equity of 273.25% and a negative net margin of 2,033.69%. The business had revenue of $0.36 million for the quarter, compared to analysts’ expectations of $11.40 million. As a group, analysts predict that Sangamo Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Sangamo Therapeutics in a research report on Thursday, August 22nd. StockNews.com assumed coverage on shares of Sangamo Therapeutics in a research report on Sunday, July 28th. They issued a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $2.67.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.